Safety of human papillomavirus (HPV) vaccines: A review of the international experience so far

Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013

“…However, monitoring of qHPV occurred between 2006 and 2009, during which a total of 600,558 doses were administered in the Vaccine Safety Database (VSD) population, and no association between qHPV and seizures, whether recurrent or new onset was observed [14]. A relatively higher reporting rate of headache was reported in Slovenia in comparison to the US and Spain (40.3 per 100,000 qHPV doses distributed vs 4.1 and 23.5, respectively), and relatively higher reporting rate of fever in comparison to the US (35.3 vs 0.4 per 100,000 qHPV doses distributed) [20,22,27]. In contrast, although local reactions are usually frequently reported AEFIs with qHPV that are generally of short duration and resolve spontaneously, in our analyses only one fifth of reports with AEFIs with qHPV involved local reactions, mainly pain and swelling [28].…”

“…Brief seizure-like events that can accompany syncopal episodes, secondary to transient hypoxia, with stiffening (tonic) movements and autonomic instability after vaccination with qHPV have been reported previously through VAERS and described in international case reports [25,27]. Reporting rate of seizures accompanying syncope after vaccination with qHPV in Slovenia was similar to the rates reported from Spain and Australia (3.4 vs 3.2 and 2.6 per 100,000 qHPV doses distributed, respectively) [22,25].…”

Le vaccin contre le virus du papillome humain chez les enfants et les adolescents

“…Depuis l'homologation de ces vaccins, des cen taines de millions de doses ont été administrées dans le monde. Les données de surveillance de l'innocuité postcommercialisa tion demeurent conformes à celles obtenues avant la commer cialisation (13). Comme dans le cas des autres vaccins, les cas d'anaphylaxie après l'administration du vaccin contre le VPH sont possibles, mais rares (14,15).…”

Update on Human Papillomavirus (HPV) Vaccines

“…No pattern of serious AEFI suggesting a causal relationship to vaccination was observed. (143) An Australian report indicates an anaphylaxis rate of 2.6 per 100 000 doses of HPV vaccine, using the stringent Brighton criteria. (144) While this rate is higher than the rates reported for other vaccines, it is still less common than the WHO categorization of adverse events which are "very rare" (1 in 10 000).…”